We are live on
!
Find out more
VA
Verdad Advisers Portfolio holdings
AUM
$88.8M
This Fund
S&P 500
This Quarter
Est. Return
+13.25%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$88.8M
AUM Growth
+$1.45M
(+1.7%)
Cap. Flow
-$2.06M
Cap. Flow
% of AUM
-2.32%
Top 10 Holdings %
Top 10 Hldgs %
21.25%
Holding
237
New
133
Increased
18
Reduced
23
Closed
58
Top Buys
| 1 |
Autohome
ATHM
|
+$2.49M |
| 2 |
BLTE
Belite Bio
BLTE
|
+$2.32M |
| 3 |
Revolution Medicines
RVMD
|
+$2.18M |
| 4 |
State Street
STT
|
+$2.13M |
| 5 |
Zymeworks
ZYME
|
+$1.96M |
Top Sells
| 1 |
Citigroup
C
|
+$4.03M |
| 2 |
TJX Companies
TJX
|
+$3.81M |
| 3 |
Johnson & Johnson
JNJ
|
+$2.79M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$2.66M |
| 5 |
Chevron
CVX
|
+$2.55M |
Sector Composition
| 1 | Healthcare | 41.87% |
| 2 | Technology | 13.22% |
| 3 | Financials | 10.56% |
| 4 | Consumer Discretionary | 7.94% |
| 5 | Communication Services | 7.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Regeneron Pharmaceuticals
REGN
$71.2B
| $219K | 0.25% |
+283
| New | +$217K |
|
127
Lincoln Educational Services
LINC
$1.4B
| $217K | 0.24% |
+5,334
| New | +$168K |
|
128
Rhythm Pharmaceuticals
RYTM
$7.28B
| $213K | 0.24% |
+2,445
| New | +$238K |
|
129
1stdibs.com
DIBS
$164M
| $208K | 0.23% |
+37,803
| New | +$209K |
|
130
Elevance Health
ELV
$80.9B
| $208K | 0.23% |
+709
| New | +$233K |
|
131
eGain
EGAN
$182M
| $207K | 0.23% |
26,288
-6,684
| -20% | -$64.6K |
|
132
Cogent Biosciences
COGT
$6.48B
| $205K | 0.23% |
+5,329
| New | +$197K |
|
133
Stewart Information Services
STC
$2.2B
| $205K | 0.23% |
+3,326
| New | +$222K |
|
134
Tactile Systems Technology
TCMD
$663M
| $204K | 0.23% |
+7,816
| New | +$223K |
|
135
BK Technologies
BKTI
$295M
| $204K | 0.23% |
+2,728
| New | +$222K |
|
|
ALMS
136
Alumis Inc
ALMS
$3.47B
| $202K | 0.23% |
+9,173
| New | +$229K |
|
137
Cullinan Oncology
CGEM
$1.01B
| $179K | 0.2% |
+12,604
| New | +$162K |
|
138
Passage Bio
PASG
$15.8M
| $174K | 0.2% |
+22,128
| New | +$229K |
|
139
Invivyd
IVVD
$232M
| $171K | 0.19% |
+131,276
| New | +$241K |
|
|
ONTF
140
DELISTED
ON24
ONTF
| $152K | 0.17% |
+18,770
| New | +$150K |
|
141
Kohl's
KSS
$1.98B
| $146K | 0.16% |
+11,282
| New | +$190K |
|
142
CytomX Therapeutics
CTMX
$798M
| $142K | 0.16% |
+30,187
| New | +$153K |
|
143
Verastem
VSTM
$507M
| $138K | 0.16% |
+26,119
| New | +$161K |
|
144
TScan Therapeutics
TCRX
$58.7M
| $135K | 0.15% |
+134,001
| New | +$143K |
|
145
Medifast
MED
$117M
| $134K | 0.15% |
+13,148
| New | +$142K |
|
146
Kodak
KODK
$765M
| $134K | 0.15% |
+14,795
| New | +$113K |
|
147
Vaalco Energy
EGY
$562M
| $132K | 0.15% |
+20,887
| New | +$105K |
|
148
NIO
NIO
$12.5B
| $129K | 0.15% |
21,450
| – | – |
|
149
Pliant Therapeutics
PLRX
$68.7M
| $124K | 0.14% |
+98,320
| New | +$124K |
|
|
DDI
150
DoubleDown Interactive
DDI
$560M
| $121K | 0.14% |
+14,322
| New | +$126K |
|
Similar funds
CAM
SCA
BFM
HI
XFP
UCM
BLC
BC
Verdad Advisers's Q1 2026 Portfolio in Review
As of Q1 2026, Verdad Advisers held 237 positions worth $88.8M, up 1.7% from $87.4M the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Verdad Advisers's Q1 2026 filing shows 133 new, 18 increased, 23 reduced and 58 closed positions. Its largest new stake was Autohome: 121,317 shares worth $2.11M. The largest sale was Citigroup, an estimated $4.03M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 12% a quarter earlier, followed by Technology and Financials.
- Verdad Advisers's largest Q1 2026 buy was Autohome: 121,317 shares worth $2.11M.
- Verdad Advisers added most to California Resources in Q1 2026, an estimated $867K increase.
- Verdad Advisers's biggest Q1 2026 reduction was Johnson & Johnson, cutting an estimated $2.79M.
- Verdad Advisers fully exited Citigroup in Q1 2026, selling an estimated $4.03M.
- Verdad Advisers's ten largest holdings make up 21% of its $88.8M portfolio in Q1 2026.
- Verdad Advisers opened 133 new positions and closed 58 in Q1 2026.
- Verdad Advisers's portfolio value rose 1.7% quarter-over-quarter to $88.8M.
Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.